Semaglutide vs Tirzepatide
Side-by-side literature comparison of a GLP-1 monoagonist (Semaglutide) and a dual GLP-1 / GIP agonist (Tirzepatide) at the receptor-pharmacology level.
Side-by-Side Attributes
Objective data pulled from the published peptide literature. For research context only — not efficacy or performance claims.
| Attribute | Semaglutide | Tirzepatide |
|---|---|---|
| Class | GLP-1 receptor monoagonist | Dual GLP-1 / GIP receptor agonist |
| Receptor targets | GLP-1R | GLP-1R + GIPR |
| Length | 31 amino acids | 39 amino acids |
| Molecular Weight | ~4113.6 Da | ~4813.5 Da |
| Lipid modification | C18 fatty diacid on Lys26 | C20 fatty diacid on Lys20 |
| Parent sequence lineage | Modified GLP-1(7-37) analogue | Chimeric backbone drawing on GIP + GLP-1 features |
| First described (public literature) | ~2012 (Novo Nordisk) | ~2018 (Eli Lilly) |
| In-vitro half-life (preclinical model reports) | Reported extended vs native GLP-1 | Reported extended vs native GLP-1 and GIP |
| Synthesis complexity | SPPS with on-resin lipidation of Lys side chain | SPPS with orthogonal protection + on-resin lipidation |
| Endotoxin release spec (BioInfinity) | < 0.5 EU/mg by LAL | < 0.5 EU/mg by LAL |
| Third-party COA lab (BioInfinity) | Verum Analytics, Switzerland | Verum Analytics, Switzerland |
Literature Context
Semaglutide and Tirzepatide are two of the most-cited incretin-family research peptides in the current metabolic-pharmacology literature. Both are engineered analogues carrying a fatty-diacid tail on a specific lysine residue that extends in-vivo half-life in preclinical animal models relative to the native peptide sequences from which they were derived.
The fundamental pharmacological difference in the published receptor literature is that Semaglutide is a single-receptor GLP-1 monoagonist, while Tirzepatide engages two receptors — GLP-1R and GIPR — with functional-selectivity that has been the subject of dozens of published in-vitro cAMP and β-arrestin recruitment studies since 2018.
Both compounds are common tool peptides in in-vitro receptor-pharmacology work: GLP-1R activation assays, GIPR cross-reactivity studies, functional-selectivity screens between the two receptors, and preclinical rodent metabolic-model literature. Neither is FDA-approved for any indication under BioInfinity supply; both are supplied strictly for laboratory research.
Research Contexts in the Literature
Overlapping
- GLP-1R binding & activation assays
- cAMP signalling pathway research
- β-arrestin recruitment studies
- Preclinical rodent metabolic-model literature
- Peptide-lipidation & PK in-vitro research
Semaglutide only
- GLP-1R monoagonist selectivity assays
- GLP-1R functional-selectivity vs full-agonism research
- GLP-1(7-37) analogue structure-activity relationship literature
Tirzepatide only
- GIP receptor pharmacology in-vitro
- GLP-1R / GIPR functional-selectivity screens
- Dual-agonist chimeric-peptide design literature
All products supplied by BioInfinity are for in-vitro laboratory research use only. Not FDA-approved. Not intended for human or veterinary use. This page is a literature summary — not medical, dosing, or usage guidance.